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Objective: We have previously shown that peripheral artery disease (PAD) is associated with marked impairment of
endothelial function (EF). Given that poor EF is associated with functional status of PAD patients as well as with
increased morbidity and mortality in patients undergoing vascular procedures, determination of factors associated with
poor EF in a PAD cohort is important. We hypothesized that decreased kidney function is associated with impaired EF in
patients with PAD.
Methods: This was a cross-sectional study of PAD patients presenting to a vascular surgery outpatient clinic at the San
Francisco Veterans Affairs Medical Center including patients enrolled in the OMEGA-PAD I trial (NCT01310270) and
the OMEGA-PAD Cohort. Brachial artery ﬂow-mediated vasodilation was performed to assess EF. Kidney function was
characterized by estimated glomerular ﬁltration rate with the abbreviated Modiﬁcation of Diet in Renal Disease formula.
Linear regression was performed to assess the relationship between EF and kidney function in claudicants.
Results: Ninety-seven patients with intermittent claudication participated in this study. Mean age was 69 6 8 years, 97%
were male, and 79% were white. Comorbidities included hypertension (91%), dyslipidemia (87%), coronary artery disease
(42%), and diabetes mellitus (38%). Mean ankle-brachial index was 0.736 0.14 and mean ﬂow-mediated vasodilation was
7.0% 6 3.8%, indicating impaired EF. Linear regression showed an association between kidney function and EF (by
10 mL/min/1.73 m2; b, 0.12; conﬁdence interval, 0.05-0.20; P [ .001). After multivariable regression adjusting for
age, race, log tumor necrosis factor a, hypertension, dyslipidemia, and diabetes, estimated glomerular ﬁltration rate
remained signiﬁcantly associated with EF (P [ .033).
Conclusions: In patients with PAD, decreased kidney function is associated with endothelial dysfunction. Further lon-
gitudinal studies are needed to better understand the impact of kidney function on PAD progression and the role of
endothelial dysfunction in this process. (J Vasc Surg 2014;60:1605-11.)Nearly one third of patients aged 70 years and older
will suffer from peripheral artery disease (PAD),1 which
can signiﬁcantly affect quality of life and longevity. Despite
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continue to have a higher risk of cardiovascular (CV)
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with patients with coronary artery disease (CAD).2 Endo-
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Table I. Baseline characteristics of the population categorized by ﬂow-mediated vasodilation (FMD) tertiles
Descriptive characteristics
All patients
(N ¼ 97)
FMD tertile I
(n ¼ 33)
FMD tertile II
(n ¼ 32)
FMD tertile III
(n ¼ 32) P valuea
Age, years 69 6 8 71 6 8 68 6 8 68 6 7 .13
Male sex, % 94 (97) 31 (94) 31 (97) 32 (100) .77
White race, % 77 (79) 26 (79) 24 (75) 27 (84) .67
BMI, kg/m2 28 6 5 30 6 6 28 6 5 28 6 5 .21
Waist-to-hip ratio, % 1.02 6 0.06 1.02 6 0.07 1.04 6 0.06 1.01 6 0.04 .28
Blood pressure, mm Hg
Systolic 138 6 18 139 6 17 143 6 18 134 6 19 .14
Diastolic 76 6 10 72 6 10 78 6 10 77 6 8 .011
Index ABI 0.73 6 0.14 0.71 6 0.17 0.73 6 0.14 0.74 6 0.11 .67
WIQ walking distance 33 6 31 36 6 35 25 6 25 36 6 32 .29
WIQ walking speed 29 6 27 28 6 28 25 6 23 34 6 31 .42
WIQ stairs 35 6 30 31 6 30 35 6 26 41 6 35 .46
ABI, Ankle-brachial index; BMI, body mass index; WIQ, Walking Impairment Questionnaire.
Mean 6 standard deviation presented for continuous variables; number of patients with relative percentage of cohort presented for categorical variables.
aP value calculated from analysis of variance for continuous variables or Fisher exact test for categorical variables.
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tions of atherosclerosis. The coprevalence of chronic kidney
disease (CKD) and PAD is high.6 Impaired kidney function
is an accepted risk factor for CV disease, and even mild
stages of CKD have been associated with adverse CV
events.7,8 For example, patients with stage 3 CKD have a
17% increase in mortality and those with stage 5 CKD
have a 600% increase in mortality compared with an age-
matched population with normal kidney function.7 Cur-
rent evidence suggests that not only is decreased kidney
function an independent predictor of CV events, it may
also be a stronger predictor than traditional risk factors.9,10
In the setting of PAD, the presence of kidney disease pre-
dicts worse outcomes after peripheral revascularization.11
Kidney disease is known to produce a state of oxidative
stress and inﬂammation,12 both of which are strong depres-
sors of EF. Whether a relationship exists between kidney
function and EF in a PAD cohort has not been established.
The current study examined the determinants of endothe-
lial dysfunction, including kidney function, in patients with
PAD. We hypothesized that kidney function could be an
important determinant of EF in patients with PAD.
METHODS
Study population and protocol
This cross-sectional study investigated the relationship
between kidney function and EF in PAD patients. The
investigator-initiated protocol was approved by the Univer-
sity of California, San Francisco, Committee on Human
Research, and all patients gave informed consent. Patients
referred to the outpatient vascular surgery clinic of the San
Francisco Veterans Affairs Medical Center (SFVAMC) for
evaluation of PAD were recruited. We included baseline
data from patients enrolled into the OMEGA-PAD trial
(NCT01310270) and the OMEGA-PAD Cohort.13 Sub-
jects were enrolled if they had at least one of the following in-
clusion criteria: intermittent claudication associated with an
ankle-brachial index (ABI) < 0.9, toe pressures < 70 mmHg, or imaging conﬁrming $50% stenosis in the lower ex-
tremity arteries. Intermittent claudication was diagnosed
on the basis of fatigue, discomfort, or pain that occurs in spe-
ciﬁc limb muscle groups during effort due to exercise-
induced ischemia.14 Exclusion criteria included end-stage
renal disease (ESRD) initiated on hemodialysis, signiﬁcant
hepatic or inﬂammatory disease, concurrent severe infec-
tions, acute illness or other major surgery within 30 days,
and taking immunosuppressive medications. We recorded
demographic and anthropometric data, CV history, risk fac-
tors, concurrentmedications, and pertinentCV examination
ﬁndings. EF was measured by brachial artery FMD, and kid-
ney function was measured by estimated glomerular ﬁltra-
tion rate (eGFR). Other measurements included lipid
markers, metabolic markers, inﬂammatory markers, omega
index, blood pressure, and bilateral ABIs.
Measurements
Demographic and anthropometric data, hemody-
namic measurements, and walking distance. Demo-
graphic and anthropometric data collected included age,
race, gender, hip and waist circumference, body mass in-
dex, prior supplement use, and exercise frequency. We
collected CV history, such as CAD, cerebrovascular dis-
ease, and previous lower extremity vascular procedures, as
well as risk factors including hypertension, diabetes mellitus
type 1 and 2, hyperlipidemia, and tobacco use based on
problem list and patient inquiry. Concurrent medications,
pertinent CV examination ﬁndings, and blood pressure
were also recorded. Walking distance and Rutherford clas-
siﬁcation were based on the patient’s self-report during
clinic visit, recorded by the investigator-vascular surgeons.
Vascular reactivity of brachial arteries. Flow-medi-
ated endothelium-dependent vasodilation was performed
according to current guidelines and standards previously
described by our group.3,13,15-17 Subjects were asked to fast
and to abstain from nicotine and caffeine before the exami-
nation. A history of recent medications was recorded. Sub-
jects were allowed to rest for 10 minutes in a supine position
Table II. Baseline comorbidities, medications, and peripheral artery disease (PAD) risk factors of the population
categorized by ﬂow-mediated vasodilation (FMD) tertiles
Characteristics
All patients
(N ¼ 97)
FMD tertile I
(n ¼ 33)
FMD tertile II
(n ¼ 32)
FMD tertile III
(n ¼ 32) P valuea
Hypertension 88 (91) 33 (100) 29 (91) 26 (81) .024
Dyslipidemia 84 (87) 30 (91) 30 (94) 24 (75) .10
History of CAD 41 (42) 19 (58) 8 (25) 14 (44) .023
Diabetes mellitus 37 (38) 17 (52) 11 (34) 9 (28) .14
Aspirin 69 (71) 26 (79) 20 (63) 23 (72) .36
ACE inhibitor 44 (45) 19 (58) 13 (41) 12 (38) .22
b-blocker 59 (61) 21 (64) 21 (66) 17 (53) .61
Statin 79 (81) 27 (82) 26 (81) 26 (81) 1.00
History of smoking, % 91 (94) 29 (88) 31 (97) 31 (97) .36
Pack-years, if applicable 48 6 34 51 6 37 49 6 37 45 6 26 .76
Cholesterol, mg/dL
Total 160 6 42 150 6 32 169 6 41 163 6 49 .16
LDL 86 6 36 75 6 28 94 6 38 91 6 40 .086
HDL 45 6 13 45 6 15 44 6 12 46 6 12 .94
Triglycerides, mg/dL 149 6 92 151 6 97 162 6 103 134 6 73 .47
ACE, Angiotensin-converting enzyme; CAD, coronary artery disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Mean 6 standard deviation presented for continuous variables; number of patients with relative percentage of cohort presented for categorical variables.
aP value calculated from analysis of variance for continuous variables or Fisher exact test for categorical variables.
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pressure cuff was placed on the upper arm proximal to the
insertion of the deltoid. The brachial artery was surveyed by
B-mode ultrasound (Philips HD11; Philips Healthcare,
Bothell,Wash)with a broadband linear array transducerwith
a 3- to 12-MHz range (Philips L12-3). Before cuff inﬂation,
the baseline diameter of the vessel was recorded with
electrocardiography-gated image capture software (Brachial
Imager; Medical Imaging Applications LLC, Coralville,
Iowa). Baseline blood ﬂow velocity was recorded with an
insonation angle of 60 degrees. The blood pressure cuff was
inﬂated to the greater of 250 mm Hg or 50 mm Hg above
the subject’s systolic bloodpressure for a periodof 5minutes.
Diameter and blood ﬂow velocity were recorded until
3 minutes after cuff release.
Analysis of the images was performed with continuous
edge-detection software (Brachial Analyzer; Medical Imag-
ing Applications LLC). Baseline diameter was recorded as
the mean of 60 seconds of data. Hyperemia diameter
was calculated by a predetermined time window of 55 to
65 seconds after cuff release. FMD% was calculated as
(60s hyperemia diameter  Avg Baseline diameter/Avg
Baseline diameter)*100.
Time-averaged velocity measurements were obtained
by the peak velocity method. Average velocity at baseline
was obtained from 60 seconds of data. Velocity of the hy-
peremia stimulus was calculated as the mean velocity of the
ﬁrst four heart beats after cuff release. Both mean velocity
and the velocity-time integral were recorded. Flow was
calculated by multiplying the time-averaged velocity by
the brachial cross-sectional area.
Quality control was assessed at each point of themeasure-
ments. Image quality was evaluated by a second person and
graded on a 6-point scale that includes registration structure
(landmark), horizontally directed artery, correct longitudinal
alignment,clearly visualizednear-wall intimal-medial thicknessand far-wall intimal-medial thickness, and at least 5 mm of
clearly visualized artery. The interobserver variability in our
laboratory is 0.05%6 0.16%, and the intraobserver variability
is 0%6 0.15%.
Kidney function. Blood samples were collected in a
fasting state for measurement of creatinine, and eGFR
was calculated with the abbreviated Modiﬁcation of Diet
in Renal Disease formula based on age, gender, race, and
serum creatinine level.18 Plasma was assayed for these
analytes on the same day as collection by the SFVAMC
laboratory per standard methodology (Beckman Coulter
Analyzer; Beckman Coulter, Inc, Miami, Fla). Subjects
with eGFR > 90 mL/min/1.73 m2 were assumed to be
CKD stage 1 because of the presence of PAD, although the
subjects did not necessarily have the conﬁrmatory kidney
damage, such as pathologic abnormalities or markers of
damage, including abnormalities in blood or urine tests or
imaging studies as set forth by the Kidney Disease Out-
comes Quality Initiative guidelines from the National
Kidney Foundation.19
ABI. The ABI was measured by current guidelines and
standards.20 Systolic blood pressures of the brachial, pos-
terior tibial, and dorsalis pedis arteries were measured
bilaterally. For each lower extremity, the highest systolic
pressure of the two pedal pulses was divided by the highest
systolic pressure of the two brachial arteries.
Lipid, metabolic, and inﬂammatory measure-
ments. Blood samples were collected in a fasting state for
measurement of albumin, total cholesterol, triglycerides,
low-density lipoprotein, high-density lipoprotein, high-
sensitivity C-reactive protein, interleukin-6, soluble intercel-
lular adhesion molecule 1, tumor necrosis factor a (TNF-a),
and hemoglobin A1c. Plasma was assayed for albumin, total
cholesterol, triglycerides, low-density lipoprotein, high-
density lipoprotein, high-sensitivity C-reactive protein, and
hemoglobin A1c on the same day as collection by the
Table III. Baseline biomarkers and brachial artery ﬂow-mediated vasodilation (FMD) study values of the population
categorized by FMD tertiles
Characteristics
All patients
(N ¼ 97)
FMD tertile I
(n ¼ 33)
FMD tertile II
(n ¼ 32)
FMD tertile III
(n ¼ 32) P valuea
CRP,b mg/dL 0.8 (0.4-1.7) 0.8 (0.5-1.4) 0.9 (0.6-1.8) 0.8 (0.3-1.7) .97
Interleukin-6,b pg/mL 0.1 (0.2 to 0.5) 0.2 (0.2 to 0.2) 0.2 (0.1 to 0.42) 0.04 (0.02 to 0.06) .75
ICAM,b ng/mL 5.5 (5.4-5.7) 5.5 (5.4-5.8) 5.5 (5.4-5.8) 5.5 (5.3-5.7) .78
TNF-a,b pg/mL 0.7 (0.5-0.9) 0.8 (0.6-1.1) 0.8 (0.5-1.0) 0.6 (0.4-0.8) .004
Homocysteine, mmol/L 14 6 4 14 6 4 14 6 5 13 6 6 .97
Albumin, g/dL 4.0 6 0.3 4.0 6 0.4 4.1 6 0.3 4.0 6 0.3 .92
Hemoglobin A1c 6.2 6 1.2 6.5 6 1.2 6.2 6 1.5 6 6 0.9 .30
Creatinine, mg/dL 1.16 6 0.67 1.41 6 1.06 1.08 6 0.29 0.98 6 0.23 .026
eGFR, mL/min/1.73 m2 74 6 21 65 6 23 74 6 19 82 6 19 .005
Baseline brachial diameter, cm 0.39 6 0.07 0.42 6 0.06 0.38 6 0.08 0.36 6 0.05 .0002
Baseline velocity, m/s 0.2 6 0.1 0.2 6 0.1 0.1 6 0.1 0.2 6 0.1 .36
Baseline ﬂow, mL/min 122 6 73 150 6 86 104 6 62 109 6 62 .018
Baseline shear stress, 12 6 6 12 6 5 12 6 8 13 6 5 .52
dynes/cm2
Hyperemia diameter, cm 0.41 6 0.07 0.44 6 0.06 0.40 6 0.08 0.40 6 0.06 .044
Hyperemia velocity, m/s 0.7 6 0.3 0.6 6 0.2 0.7 6 0.3 0.8 6 0.2 .0001
Hyperemia ﬂow, mL/min 576 6 307 531 6 318 554 6 327 645 6 273 .29
Hyperemia shear stress, dynes/cm2 48 6 20 36 6 15 48 6 19 59 6 18 <.0001
Brachial FMD, % 7.0 6 3.8 3.0 6 1.2 6.7 6 0.9 11.4 6 2.4 d
CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; ICAM, intercellular adhesion molecule; TNF-a, tumor necrosis factor a.
aP value calculated from analysis of variance and mean 6 standard deviation presented for continuous variables.
bInﬂammatory marker levels not normally distributed were log-transformed and presented as median (interquartile range).
Fig. Relationship between chronic kidney disease (CKD) and
endothelial function (EF) in a cohort of patients with peripheral
artery disease (PAD). CKD stages are deﬁned according to the
Kidney Disease Outcomes Quality Initiative guidelines.19 FMD,
Flow-mediated vasodilation.
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Coulter Analyzer). The coefﬁcient of variation for high-
sensitivity C-reactive protein with this procedure is 5.1%.
Serum was isolated at the same time points for homocysteine
and assayed the same day as collection by the SFVAMC lab-
oratory per standardmethodology (Architect i1000Analyzer;
Abbott Diagnostics, Lake Forest, Ill). Serum was processed
per standard protocol and stored at 80C until assayed for
interleukin-6, soluble intercellular adhesion molecule 1, and
TNF-a per standard kit protocol (R&D Systems Inc, Min-
neapolis, Minn). The typical coefﬁcients of variation for
interleukin-6, soluble intercellular adhesion molecule 1, and
TNF-a are 7.4%, 4.6%, and 5.4%, respectively. The lower
limits of detection are 0.04 pg/mL, 0.1 ng/mL, and
0.11 pg/mL, respectively.
Statistical analysis
For descriptive purposes, we categorized participants
by FMD tertiles. Inﬂammatory markers not normally
distributed were log-transformed. Differences in character-
istics among FMD tertiles were compared by analysis of
variance for continuous variables and Fisher exact test for
dichotomous variables. For the overall regression models,
patients were divided into FMD tertiles. We used linear
regression models to examine the relationship between all
variables listed in Table I and FMD tertiles. eGFR was
treated as a continuous linear variable in the regression
models; graphical diagnostics such as spline regression plots
supported this decision. Multivariate adjustment was made
for demographic characteristics and traditional CV risk fac-
tors on the basis of an a priori determination of P < .1 in
univariate models. An a priori determination of signiﬁcanceat P < .05 was used in the multivariate model. Statistical
analyses were performed with Stata/SE 12 (StataCorp,
College Station, Tex).
RESULTS
A total of 97 patients with intermittent claudication
participated in this study. Tables I and II demonstrate
the demographics, comorbidities, medications, and
PAD risk factors by FMD tertiles. The mean age was
696 8 years, 97% were male, and 79% were white. Comor-
bidities included hypertension (91%), dyslipidemia (87%),
Table IV. Determinants of endothelial function (EF) in univariate and multivariate linear regression analysis
Univariate analysis (n ¼ 97) Multivariate analysis (n ¼ 84)
Independent variable b Coefﬁcienta 95% CI P value b Coefﬁcienta 95% CI P value
Age, by decade 0.19 0.41 to 0.02 .082 0.009 0.230 to 0.211 .93
Race .33 .52
White (reference)
African American 0.2 0.4 to 0.7 0.04 0.53 to 0.46
Hispanic 0.5 1.2 to 0.2 0.39 1.03 to 0.25
Asian/Paciﬁc Islander 0.5 1.7 to 0.7 0.50 1.58 to 0.57
Hypertension 0.7 1.3 to 0.2 .009 0.5 1.1 to 0.1 .085
Diabetes mellitus 0.333 0.669 to 0.004 .052 0.04 0.39 to 0.31 .81
Dyslipidemia 0.46 0.94 to 0.02 .063 0.45 0.96 to 0.06 .082
TNF-ab, pg/mL 0.9 1.4 to 0.4 .001 2.07 5.10 to 0.97 .18
D10 mL/min/1.73 m2 eGFR 0.12 0.05-0.20 .001 0.101 0.008-0.193 .033
CI, Conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; TNF-a, tumor necrosis factor a.
aThe b coefﬁcients of the multivariable model represent the change in percentage of ﬂow-mediated vasodilation (FMD) due to the presence of a variable (race,
hypertension, or 10 mL/min/1.73 m2 change in eGFR).
bInﬂammatory marker levels not normally distributed were log-transformed.
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74 6 21 mL/min/1.73 m2, and mean index ABI was
0.73 6 0.14. Mean FMD was 7.0% 6 3.8% (Table III),
indicating impaired EF compared with the normal range
of 10% to 13%.21 With decreased kidney function, there
was a decrease in FMD (I: 65, II: 74, III: 82 mL/min/
1.73 m2; P ¼ .012; Fig).
By univariate analysis (Table IV), age (by decade;b,0.19;
95% conﬁdence interval [CI], 0.41 to 0.02; P ¼ .082),
hypertension (b, e0.7; 95% CI, e1.3 to e0.2; P ¼ .009),
diabetes mellitus (b, e0.333; 95% CI, e0.669 to 0.004;
P ¼ .052), dyslipidemia (b, e0.46; 95% CI e0.94 to 0.02;
P ¼ .063), log TNF-a (b, 0.9; 95% CI, 1.4 to 0.4;
P ¼ .001), and eGFR (by 10 mL/min/1.73 m2; b, 0.12;
95% CI, 0.05-0.20; P ¼ .001) were associated with EF.
Aftermultivariate linear regression adjusting for age, race,
log TNF-a, and hypertension, only eGFR remained signiﬁ-
cantly associated with FMD (P¼ .033; Table IV). A decrease
of 10mL/min/1.73m2 in eGFRwas associatedwith a 0.12%
decrease in FMD with a 95% CI of 0.008 to 0.193.
DISCUSSION
In a cross-sectional cohort study of patients presenting
to our outpatient vascular surgery clinic with PAD, we
found a signiﬁcant association between kidney function
and EF as measured by brachial artery FMD in patients
with PAD. Among PAD patients with claudication, those
with CKD have the worst EF. In view of the high risk asso-
ciated with PAD,2 a better understanding of the relation-
ship between kidney function and endothelial dysfunction
could be clinically relevant.
Factors inﬂuencing EF. Traditional risk factors for
atherosclerosis, including diabetes, hyperhomocysteinemia,
hypertension, dyslipidemia, and smoking, are also known
to affect EF.22-26 Our analysis suggests that kidney dis-
ease may be a particularly strong and independent risk
factor for endothelial dysfunction in the PAD population.Several clinical studies have explored the relationship be-
tween kidney failure and endothelial dysfunction. Nakamura
et al27 found that EF assessed by brachial FMD was associ-
ated with kidney disease in patients with CAD. They also
suggested that systemic EF may precede the development
of kidney disease in patients with normal kidney function.
In a cohort of patients with essential hypertension, Perticone
et al28 found an impaired vasodilatory response to acetylcho-
line associated with moderate kidney disease. Kari et al29
found lower brachial FMD, higher endothelial nitric oxide
synthase inhibitors, and lower nitric oxide metabolites in a
small nonatherosclerotic cohort of 23 children with CKD.
An ESRD cohort of 44 subjects on hemodialysis for at least
3 months was compared with 25 controls, showing that
ESRD is associated with lower shear stress, compliance,
andbrachial FMDby the hand-warming technique.30Wever
et al31 found endothelial dysfunction as assessed by dimin-
ished whole body nitric oxide production in seven CKD pa-
tients compared with seven controls. Kidney function and
EF have been associated in various CAD and CKD popula-
tionswith varying techniques of evaluatingEF.Nevertheless,
this relationship has not been studied in the PADpopulation.
Mechanisms of endothelial dysfunction in kidney
disease. Endothelial dysfunction is considered to be a sys-
temic issue. In glomerular endothelial cells, albuminuria
leads to a reduction in the endothelium-dependent
vascular relaxation response in the kidney.32 Whether kid-
ney endothelial dysfunction precedes systemic EF, or vice
versa, is controversial.27 The key markers responsible for
this cascade between kidney and systemic endothelial
dysfunction are likewise unclear. Potential mediators be-
tween kidney function and EF include asymmetric dime-
thylarginine (ADMA) and TNF-a.
Kidney failure permits an accumulation of competitive
inhibitors of endothelial nitric oxide synthase, namely,
ADMA.33 ADMA is raised in ESRD and could contribute
to higher CV risk in patients with chronic kidney failure.33
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EF assessed by brachial FMD in patients with PAD34 and
independently predict arterial stiffness.26 Elevated ADMA
concentrations predict progression of both CKD and
PAD.35 ADMA accumulation leads to increased production
of inﬂammatory markers such as TNF-a and interleukin-6
and interleukin-8 as well as the binding of monocytes to
endothelial cells.33 Furthermore, inﬂammation inhibits the
enzyme that degrades ADMA, contributing to a vicious cir-
cle of ADMA accumulation and increased inﬂammation.33
It is therefore not surprising that our study suggests
that TNF-a, a well-known marker of inﬂammation, may
play a role as a link between EF, CKD, and PAD. TNF-a
is associated with greater incidence of PAD and is known
to act independently on human endothelial cells.2,36
TNF-a also predicts mortality in acute kidney failure and
progression to ESRD.37 The median TNF-a in our cohort
was 2.11 pg/mL (interquartile range, 1.68-2.47), which is
higher than normal levels around 1.81 pg/mL (interquar-
tile range, 1.29-2.33).38 Our univariate analysis supports
EF as an inﬂammatory process, showing an association
with log TNF-a. However, it is currently uncertain
whether TNF-a is speciﬁcally involved in the pathway for
CKD.37 Further studies need to be done to identify the
role of TNF-a in CKD and PAD.
Clinical implications. Studies have shown that
decreased kidney function is an independent and signiﬁcant
predictor of outcomes in patients after peripheral revascular-
ization.11 Kidney function has increasingly displayed greater
predictive value of CV events in patients with atherosclerosis
than traditional risk factors.9,10 Kidney failure patients have
extremely low FMD, even more so than that of PAD pa-
tients.29 Once advanced kidney disease is present, it may
contribute to the progression of systemic endothelial
dysfunction more than traditional CV risk factors do.
To our knowledge, this report is the ﬁrst to examine
the relationship between kidney function and EF evaluated
by brachial artery FMD in a PAD cohort. Several studies
have found impaired vasodilatory response to be associated
with loss of kidney function in other cohorts or with tech-
niques other than brachial artery FMD through reactive
hyperemia.27-31 Because several studies have characterized
impaired EF in the ESRD population requiring hemodial-
ysis, we focused on earlier stages of CKD and were able to
detect an association. We therefore conﬁrm through this
cross-sectional study that kidney function could serve as a
strong risk marker for EF in PAD patients with intermittent
claudication. This cohort will continue to be observed
longitudinally to determine if there is an association be-
tween kidney function and EF over time.
Limitations. The patient population studied was not
representative of the wider PAD population as it included
only veterans who were mostly male and white referred
to a vascular surgery clinic at the SFVAMC. This study
does not address the majority of patients with PADdthose
who are asymptomatic. Likewise, it also does not examine
the most severe end of the PAD spectrum, critical limb
ischemia. Although patients were evaluated for PAD,FMD was assessed not in the lower extremity but in the
brachial artery. Nevertheless, Anderson et al39 found that
brachial FMD modeled FMD in the coronary arteries as
well, indicating that brachial FMD is predictive of systemic
EF. Whereas a history of recent antihypertensive and an-
tiplatelet medications was recorded, cilostazol and nitrates
were not included. In addition, walking distance was
assessed on the basis of subjective self-report, rendering a
large error within each FMD tertile. We are currently
adding the 6-minute walk test to better understand the
relationship between walking and EF. Furthermore, the
population studied may be skewed compared with the
typical PAD patient with regard to the psychological proﬁle
of patients, affecting overall stress and inﬂammation.40
Although the sample size is modest, it is larger than all
but one trial studying the effects of kidney disease on EF as
assessed by FMD. Most important, this report does not
imply causation but rather an association.
CONCLUSIONS
In patients with PAD and claudication, those with
CKD have the worst endothelial dysfunction as measured
by FMD. As such, kidney function is as important a risk
factor as traditional PAD risk factors. Longitudinal studies
are needed to explore the relationship between declining
kidney function and progression of PAD over time and
whether these are both associated with or driven by pro-
gressive impairments in EF.
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